AstraZeneca bags Imfinzi okay in big Chinese lung cancer marketChina has approved AstraZeneca’s PD-1/PD-L1 inhibitor Imfinzi to treat small-cell lung cancer (SCLC), an aggressive form of the Share XAstraZeneca bags Imfinzi okay in big Chinese lung cancer markethttps://pharmaphorum.com/news/astrazeneca-bags-imfinzi-okay-in-big-chinese-lung-cancer-market/
Roche’s Tecentriq gets fourth European NSCLC indicationRoche’s cancer immunotherapy Tecentriq has been granted a new use by European regulators, for the first-line treatment of Share XRoche’s Tecentriq gets fourth European NSCLC indicationhttps://pharmaphorum.com/news/roches-tecentriq-gets-fourth-european-lung-cancer-indication/
Tecentriq can stay as therapy for triple-negative breast cancer, FDA experts sayRoche’s Tecentriq can stay on the US market as a therapy for triple negative breast cancer, advisers to Share XTecentriq can stay as therapy for triple-negative breast cancer, FDA experts sayhttps://pharmaphorum.com/news/tecentriq-can-stay-as-therapy-for-triple-negative-breast-cancer-fda-experts-say/
Roche’s Tecentriq loses bladder cancer use as FDA crackdown continuesRoche’s Tecentriq is the latest medicine to fall foul of a crackdown by the FDA on drugs that Share XRoche’s Tecentriq loses bladder cancer use as FDA crackdown continueshttps://pharmaphorum.com/news/roches-tecentriq-loses-bladder-cancer-use-as-fda-crackdown-continues/
NICE okays Roche liver cancer immunotherapy, Sanofi’s rare disease drugPreviously-untreated patients with hepatocellular carcinoma (HCC), a common form of liver cancer, will have an immunotherapy-based treatment option Share XNICE okays Roche liver cancer immunotherapy, Sanofi’s rare disease drughttps://pharmaphorum.com/news/nice-okays-roche-liver-cancer-immunotherapy-sanofis-rare-disease-drug/
Roche’s Tecentriq flunks triple-negative breast cancer trialRoche’s hopes of extending the use of its PD-L1 inhibitor Tecentriq in triple-negative breast cancer (TNBC) have been Share XRoche’s Tecentriq flunks triple-negative breast cancer trialhttps://pharmaphorum.com/news/roches-tecentriq-flunks-triple-negative-breast-cancer-trial/
Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surgeRoche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma – Share XRoche’s Tecentriq claims melanoma OK, but don’t expect a sales surgehttps://pharmaphorum.com/news/roches-tecentriq-claims-melanoma-ok-but-dont-expect-a-sales-surge/
Roche’s Tecentriq cocktail fails in newly-diagnosed ovarian cancerA cocktail of drugs including Roche’s Tecentriq has failed to improve progression-free survival in ovarian cancer patients, before or after surgery. Roche had Share XRoche’s Tecentriq cocktail fails in newly-diagnosed ovarian cancerhttps://pharmaphorum.com/news/roches-tecentriq-cocktail-fails-in-newly-diagnosed-ovarian-cancer/
Roche’s Tecentriq/Avastin combo gets liver cancer nodThe FDA has approved Roche’s combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular carcinoma (HCC) – Share XRoche’s Tecentriq/Avastin combo gets liver cancer nodhttps://pharmaphorum.com/news/roches-tecentriq-avastin-combo-gets-liver-cancer-nod/
